Published :
Updated :
For all latest news, follow The Financial Express Google News channel.
NIPRO JMI Pharma Ltd (NJP) has recently arranged a scientific seminar titled ‘Management of diabetes during ramadan and Empagliflozin – A groundbreaking innovation for T2DM’ at Asgar Ali Hospital in the capital.
Professor Dr Zabrul SM Haque, CEO and Director, Medical Services, Asgar Ali Hospital was present as chairperson at the seminar, said a media release.
Other renowned doctors also attended the function.
Speaking on the occasion, Dr Rushda Sharmin Binte Rouf discussed about the advantages and benefits of Empagliflozin drugs in diabetes management, its use during Ramadan and its cardiovascular benefits.
The drug is now being prescribed in USA, Canada, Australia, Europe and other parts of the world, she added.
Md Mizanur Rahman, Chief Executive Officer of the NIPRO JMI Pharma Ltd. expressed his gratitude to all participants and said that NJP will launch more new molecule in future for the well-being of the ailing humanity.